bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.10.13.682247

Targeting multidrug-resistant bacteria with genetic-information-free protein-only phages

Abstract

Bacteriophages offer advantages over small-molecule antibiotics, including host specificity and general compatibility with the human phagenome. However, their evolvability as replicating biological entities introduces therapeutic unpredictability and risks of phage-bacteria co-evolution. Here, we retain the targeting benefits of phages while avoiding genetic replication by engineering genetic-information-free, protein-only phages (POPs). These genome-free particles self-assemble in a cell-free protein synthesis system from modular, de novo gene fragments encoding only structural and antimicrobial proteins. Using Enterobacteria phage T7 and its susceptible bacterial host as a model, we test the hypothesis that POPs stochastically encapsulate small antimicrobial proteins during self-assembly and deliver them into bacteria during adsorption via an ejectome-mediated injection mechanism. A computational survey of T7 small proteins revealed early and mid-genome enrichments of hypothetical proteins and capsid volume sufficient to accommodate multiple small proteins in the absence of the [~]40-kb genome. In time-series antimicrobial susceptibility assays (48-72 h), POPs produced initial growth inhibition comparable to wild-type T7 at the highest doses with a linear dose-effect relationship and a minimum inhibitory concentration-like threshold. These results establish the feasibility of genetic-information-free POPs as protein-based antimicrobials that couple phage receptor specificity with minimal biosafety risks, supporting the development of more stable and predictable phage-inspired therapeutics.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Batres, J., Hunter, B., Shim, H.. 2025-10-15. Targeting multidrug-resistant bacteria with genetic-information-free protein-only phages. https://doi.org/10.1101/2025.10.13.682247

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Negative allosteric modulation of α5-GABAA receptors engages dynamic cortical glutamatergic and GABAergic mechanisms underlying adaptive behavior in mice

Chronic stress disrupts glutamatergic and GABAergic plasticity in the medial prefrontal cortex (mPFC), impairing circuit integration and contributing to the pathophysiology of stress-related disorders, such as Major Depressive Disorder (MDD). Rapid-acting antidepressants like ketamine can rapidly reverse these deficits, but its clinical use is limited by psychotomimetic side effects. Notably, the 5-GABAAR negative allosteric modulator (5-NAM) Basmisanil (BSM), reproduces ketamine-like behavioral outcomes in preclinical models, although the cellular mechanisms underlying its actions remain unclear. Here, we investigated whether BSM promotes ketamine-like enhancement of cortical plasticity and engages cell type-specific mechanisms to support adaptive behaviors over time. We show that BSM produced rapid and sustained facilitation of motivational, hedonic, and active coping behaviors via mPFC circuits. BSM induced c-Fos expression in mPFC D1R- and somatostatin-expressing cells, suggesting activation of specific subsets of pyramidal and GABA interneurons. In both mPFC and hippocampus, BSM rapidly activated Erk- or Akt-mTOR signaling pathways as well as increased synaptic proteins critical for glutamatergic and GABAergic function. BSM also reversed maladaptive behaviors induced by chronic unpredictable stress, including impairment in object recognition memory and social interaction. Finally, chemogenetic silencing of mPFC CaMKII-expressing neurons blocked both rapid and sustained actions of BSM, whereas inhibition of mPFC GABA interneurons reversed only long-term behavioral outcomes. These results indicate that 5-GABAAR modulation requires early activation of pyramidal neurons to drive rapid plasticity, while GABAergic adaptations support sustained improvements. This dynamic mechanism restores excitation-inhibition (E/I) balance and highlights GABAergic pathways as therapeutic targets for prefrontal dysfunction in stress disorders.

pharmacology and toxicology↗